Celcuity
Develops and prepares to commercialize gedatolisib therapies for advanced breast and prostate cancers.
$90.10
After-hours close+1.60 (+1.81%)
At close$88.50(−5.08%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 121.02%Insiders 6.02%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 48.77M · Float 29.91M · 61.3% free float
Institutions13F, as of Jun 30, 2026
288 holders · 59.02M shares · 63 new positions · 174 increased · 81 reduced · 60 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 7.92M | 16.23% | 0 | Aug 14, 2026 |
| Avoro Capital Advisors LLC | 3.40M | 6.97% | +25.0K | Aug 14, 2026 |
| RTW Investments, LP | 3.30M | 6.78% | +265.3K | Aug 14, 2026 |
| Perceptive Advisors LLC | 3.20M | 6.56% | +70.0K | Aug 14, 2026 |
| BlackRock, Inc. | 3.02M | 6.19% | +307.3K | Aug 7, 2026 |
| State Street Corp | 1.96M | 4.01% | +436.6K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 1.87M | 3.84% | +91.2K | Aug 13, 2026 |
| Nea Management Company, LLC | 1.71M | 3.51% | −575.0K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 9.99% | 4.88M | 13G | Jul 16, 2026 ↗ |
| Brian F. Sullivan | 9.10% | 4.01M | 13G | Nov 13, 2025 ↗ |
| Perceptive Advisors LLC | 6.80% | 3.16M | 13G | Feb 17, 2026 ↗ |
| Avoro Capital Advisors LLC | 6.72% | 3.11M | 13G | Feb 17, 2026 ↗ |
| Bank of America Corp /DE/ | 6.50% | 3.17M | 13G | Aug 11, 2026 ↗ |
| RTW Investments, LP | 6.30% | 3.04M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.90% | 2.18M | 13G | Feb 4, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Brian F. Sullivan | director, officer: Chief Executive Officer | 1.45M | 2.97% | Aug 18, 2026 |
| Lance G. Laing | director, officer: Chief Science Officer | 1.27M | 2.61% | Aug 18, 2026 |
| Baker Bros. Advisors LP | other: Former 10% owner | 442.9K | 0.91% | Jul 16, 2026 |
| Richard Nigon | director | 80.6K | 0.17% | Jun 9, 2026 |
| David Dalvey | director | 66.5K | 0.14% | Jun 9, 2026 |
| Vicky Hahne | officer: Chief Financial Officer | 37.8K | 0.08% | Aug 18, 2026 |
| Leo Furcht | director | 12.5K | 0.03% | Jun 9, 2026 |
| Richard E. Buller | director | 9.3K | 0.02% | Jun 9, 2026 |
| Polly A. Murphy | director | 6.5K | 0.01% | Jun 9, 2026 |
| Charles R. Romp | director | 1.7K | 0.00% | Jun 9, 2026 |
1 ten-percent owner holds 442.9K shares by Form 4 — the 13D/G table above shows that stake, the figure above counts officers and directors only · 1 person has not refiled in the last 18 months (7.8K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 14, 2026 | Baker Bros. Advisors LPother: Former 10% owner | Sale · 2 lots | 3,100,000 | $102.50 | 442,940 |
| May 4, 2026 | Richard E. Bullerdirector | Sale · 6 lots | 9,000 | $140.46 | 6,760 |
| May 4, 2026 | David Dalveydirector | Sale | 25,000 | $140.68 | 65,000 |
| Mar 31, 2026 | Richard E. Bullerdirector | Sale · 2 lots | 3,000 | $110.27 | 6,760 |
| Jan 27, 2026 | David Dalveydirector | Sale | 20,000 | $120.03 | 90,000 |
| Dec 5, 2025 | Richard E. Bullerdirector | Sale · 2 lots | 3,000 | $105.69 | 6,760 |
| Dec 1, 2025 | Richard E. Bullerdirector | Sale | 1,100 | $98.13 | 7,260 |
| Nov 21, 2025 | David Dalveydirector | Sale | 15,000 | $100.00 | 110,000 |
| Nov 20, 2025 | Richard E. Bullerdirector | Sale | 3,900 | $96.73 | 7,260 |
| Sep 8, 2025 | Baker Bros. Advisors LP10 percent owner | Purchase · 4 lots | 170,100 | $56.27 | 7,211,484 |
CongressHouse and Senate disclosures
Not reported.